Changes in smoking cessation assistance in the European Union between 2012 and 2017: pharmacotherapy versus counselling versus e-cigarettes by Filippidis, FT et al.
1Filippidis FT, et al. Tob Control 2018;0:1–6. doi:10.1136/tobaccocontrol-2017-054117
Changes in smoking cessation assistance 
in the European Union between 2012 and 
2017: pharmacotherapy versus counselling 
versus e-cigarettes
Filippos T Filippidis,1,2 Anthony A Laverty,1 Ute Mons,3 Carlos Jimenez-Ruiz,4 
Constantine I Vardavas2,5,6
Research paper
To cite: Filippidis FT, 
Laverty AA, Mons U, et al. 
Tob Control Epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
tobaccocontrol-2017-054117
1Public Health Policy Evaluation 
Unit, School of Public Health, 
Imperial College London, 
London, UK
2Center for Health Services 
Research, School of Medicine, 
National and Kapodistrian 
University of Athens, Athens, 
Greece
3Cancer Prevention Unit and 
WHO Collaborating Centre 
for Tobacco Control, German 
Cancer Research Center, 
Heidelberg, Germany
4Smoking Cessation Service, 
Community of Madrid, Madrid, 
Spain
5Institute of Public Health, 
American College of Greece, 
Athens, Greece
6Nicotine Dependence Center, 
Mayo Clinic, Rochester, 
Minnesota, USA
Correspondence to
Dr Filippos T Filippidis, 
Department of Primary Care 
and Public Health, School of 
Public Health, Imperial College 
London, London W6 8RP, UK;  
 f. filippidis@ imperial. ac. uk
Received 25 October 2017
Revised 25 February 2018
Accepted 26 February 2018
AbsTRACT
background The landscape of smoking cessation may 
have changed in Europe recently.
Objectives To identify changes in use of smoking 
cessation assistance in the European Union (EU) and 
factors associated with use of cessation assistance.
Methods Data from the 2012 (n=9921) and 
2017 (n=9489) waves of the Eurobarometer survey 
were used. Self-reported use of smoking cessation 
assistance was assessed among smokers who had ever 
tried to quit and former smokers. Changes in use of 
each type of assistance were assessed using logistic 
regression.
Results Among current and former smokers, those who 
had ever attempted to quit without assistance increased 
from 70.3% (2012) to 74.8% (2017). Current smokers 
were more likely to have used any assistance compared 
with former smokers (P<0.001). Use of e-cigarettes 
for smoking cessation assistance increased (3.7% to 
9.7%)%), while use of pharmacotherapy (14.6% to 
11.1%)%) and smoking cessation services (7.5% to 
5.0%)%) declined. Younger people were more likely to 
have reported e-cigarette use for smoking cessation but 
less likely to have used a cessation service. Individuals 
living in countries with comprehensive smoking cessation 
policies were more likely to have used any cessation 
assistance (adjusted OR (aOR)=1.78; 95% CI 1.15 
to 2.76), pharmacotherapy (aOR=3.44; 95% CI 1.78 
to 6.66) and smoking cessation services (aOR=2.27; 
95% CI 1.27 to 4.06) compared with those living in 
countries with weak smoking cessation policies.
Conclusions These findings highlight the need for 
approaches that ensure that smokers get support to 
quit smoking across the EU. The question of whether the 
availability of e-cigarettes will displace other methods, 
and the impact of such a displacement, should be closely 
evaluated.
InTROduCTIOn
The WHO has selected a 30% reduction in tobacco 
use as one of the 25 by 2025 goals, and the WHO 
Regional Office for Europe has professed their 
ultimate goal to have a European region free of 
tobacco use.1 Smoking cessation is thus a core 
activity for population health and entails substan-
tial health benefits both for individual smokers and 
public health. Smoking cessation has additionally 
been recognised as an essential component of the 
WHO’s MPOWER package for tobacco control 
and the WHO Framework Convention for Tobacco 
Control (FCTC).2 
There is, however, wide variation between EU 
Member States (EU MS) in both their smoking prev-
alence and in the extent of their tobacco control 
policies. A 2014 review identified gaps in the imple-
mentation of the FCTC in Europe, including high-
lighting concerns that the region was progressing 
slowly in terms of providing comprehensive cessa-
tion services—an important aspect of FCTC Article 
14.3 A previous analysis of Eurobarometer data 
across the EU found that the majority of smokers 
who were trying to quit tobacco use were not using 
assistance. Moreover, the use of cessation assistance 
varies among countries, depending in part on their 
policies regarding access to cessation methods.4 This 
variation in provision of cessation assistance has 
raised concerns over how people are attempting to 
quit, especially if they are unable to access evidence-
based smoking cessation methods. This is particu-
larly important for clinicians dealing with patients 
trying to quit with a variety of methods for which 
they may have little experience or limited evidence.
In light of this gap, we conducted secondary anal-
yses of pooled Eurobarometer datasets from 2012 
and 2017 in order to assess the changing landscape 
of smoking cessation assistance used across EU MS 
during the past 5 years among current and former 
smokers. As a secondary outcome, we also inves-
tigated potential EU MS-specific changes in the 
use of cessation assistance and sociodemographic 
factors associated with the use of particular types 
of assistance.
MeThOds
data source
We analysed data from 27 EU MS, collected 
in two Eurobarometer surveys: wave 77.1 
(February–March 2012) and wave 87.1 (March 
2017).5 6 All Eurobarometer surveys employ a 
multistage sampling design in each MS according 
to which primary sampling units (PSUs) are selected 
from each region within each country, propor-
tional to population size. Subsequently, a sample 
of starting addresses is randomly selected in each 
PSU, and households are systematically selected 
following a standard random route starting from 
these initial addresses. One participant in each 
household is randomly selected and interviewed 
in the local language. The methodology has been 
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consistent across Eurobarometer waves. The European Commis-
sion does not publish response rates; however, poststratification 
and population size weighting were applied in each country/
region to produce nationally representative samples in terms 
of age, gender and area of residence. A total of n=26 751 and 
n=26 853  individuals  aged  ≥15  years  from  27  EU MS  were 
interviewed in 2012 and 2017, respectively. A total of 19 410 
respondents (9921 in 2012 and 9489 in 2017) were included in 
the analysis as either former smokers or current smokers who 
reported a previous quit attempt. Interviews in Croatia, the 28th 
EU MS, were only conducted in 2017; therefore, it was excluded 
from this analysis.
Measures
Tobacco smoking
All respondents were asked ‘Regarding smoking cigarettes, cigars 
or a pipe, which of the following applies to you?’. Responses 
included ‘You currently smoke’ (ie, current smokers); ‘You used 
to smoke but you have stopped’ (ie, former smokers); and ‘You 
have never smoked’ (ie, never smokers).
Use of cessation assistance
Former smokers, as well as current smokers who had ever tried 
to quit smoking in the past were asked: ‘Which of the following 
did you use in order to quit or to try to quit smoking?’. Respon-
dents could choose one or more responses. Wording of some 
responses differed slightly between the two surveys, but for the 
purpose of this analysis, we grouped them as follows: (A) medica-
tion, including nicotine replacement medications (nicotine gum, 
patch, inhaler and so on (nicotine replacement therapy  (NRT))) 
or other medications (’Pharmacotherapy’); (B) health services, 
including support from the doctor or other health professional 
or special stop-smoking services (clinics, specialists, quitlines and 
so on) (‘Smoking cessation services’); (C) oral tobacco (snus), 
chewing or nasal tobacco (snuff) (‘Oral or nasal tobacco’); (D) 
electronic cigarettes or similar devices (‘Electronic cigarettes’); 
(E) other; and (f) you quit or you tried to quit without assistance 
(‘Without assistance’). Respondents who mentioned at least one 
of options (A) to (E) were classified as having used any smoking 
cessation assistance in the past.
Sociodemographic data
Respondents also provided data on their age (15–24, 25–39, 
40–54  and ≥55  years),  sex  (male;  female),  age  at which  they 
stopped  full-time education  (≤15, 16–19 and ≥20 years old), 
their difficulties to pay bills during the last 12 months (almost 
never/never and from time to time/most of the time) and area of 
residence (rural and urban).
National cessation policies
We collected data on national smoking cessation policies from 
the Tobacco Control Scale (TCS) 20137 and 2016,8 which 
score European countries according to their tobacco control 
policies. We used the score for the subscale ‘treatment to help 
smokers stop’, which can range from 1 to 10 points and evalu-
ates recording of smoking status in medical notes (1 point); brief 
advice in primary care (1 point); quitline (2 points); network of 
smoking cessation support and its reimbursement (4 points); and 
reimbursement of medications (2 points). We classified member 
states into three categories: low (1–4), medium (5–7) and high 
TCS treatment score (8–10). Country-specific scores varied very 
little between 2013 and 2016; therefore, the classification for 
each member state was consistent over time. Ireland was the only 
country that could be potentially classified into two categories (7 
points in 2013 and 8 points in 2016). We used the most recent 
score to classify it as a high-scoring country.
statistical analysis
We restricted our analysis to former smokers and current 
smokers who reported having tried to quit in the past. Descrip-
tive results are presented as % with 95% CIs and regression 
results as adjusted ORs with 95% CI. Proportions are compared 
with χ2 tests. Multilevel logistic regression models with country 
as the higher level of analysis were fitted to assess the association 
between independent variables (age, sex, education, difficulty 
paying bills, area of residence, TCS treatment score and year of 
survey) and each of the following outcomes: (A) having used any 
cessation assistance; (B) having tried to quit without assistance; 
(C) having used pharmacotherapy; (D) having used smoking 
cessation services; and (E) having used electronic cigarettes or 
similar devices. The multilevel model controls for clustering 
within countries. An interaction term between TCS treatment 
score and calendar year was included to explore whether change 
in use of cessation assistance differed according to comprehen-
siveness of smoking cessation policies. Associations with the 
remaining cessation types of assistance were not assessed, as the 
number of responses was too low to be able to draw any reliable 
results. Separate models, adjusting for the same variables, were 
run for each EU MS to assess differences between 2012 and 2017 
in the reported use of the three most commonly reported types 
of assistance: pharmacotherapy, smoking cessation services and 
electronic cigarettes. Finally, correlation coefficients between 
country level changes (ie, change in ever use between 2012 and 
2017 as a percentage of the 2012 value) in ever use of phar-
macotherapy, smoking cessation services and e-cigarettes were 
calculated. All analyses were performed with Stata V.14.0, and 
weights provided in the Eurobarometer dataset were used in 
descriptive analyses to account for the complex sampling design 
of the survey.
ResulTs
Among current and former smokers, the majority of respondents 
had tried to quit without assistance both in 2012 (70.3%) and in 
2017 (74.8%) (table 1). Pharmacotherapy was the most popular 
cessation assistance (14.6% in 2012 and 11.1% in 2017), 
followed by electronic cigarettes and cessation services. More 
current smokers who had attempted to quit reported having 
used any cessation assistance compared with former smokers 
both in 2012 (40.4% vs 25.6%, P<0.001) and in 2017 (37.5% 
vs 20.8%, P<0.001). Among those who had ever used any assis-
tance to quit smoking, 16.6% of respondents in 2012 and 12.1% 
in 2017 (P<0.001) reported having ever used more than one 
type of assistance. Including ‘without assistance’ as a cessation 
method, 9.5% of our sample in 2012 and 6.0% of our sample in 
2017 reported having used multiple methods to quit (P<0.001). 
In 2017, 35.3% of those who had ever used pharmacotherapy, 
34.9% of those who had ever used cessation services, 32.1% 
of those who had ever used e-cigarettes to quit and only 4.1% 
of those who had ever tried without assistance reported having 
tried to quit with multiple methods.
Former smokers and current smokers who had tried to quit 
were less likely to have used any cessation assistance in 2017, 
compared with 2012 (aOR=0.61; 95% CI 0.52 to 0.71) and 
consequently more likely to have tried quitting without any assis-
tance (aOR=1.72; 95% CI 1.47 to 2.02), but these changes were 
attenuated in countries with medium and high TCS treatment 
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scores as shown by the interaction terms of TCS treatment score 
and year (table 2). The reported use of e-cigarettes as cessation 
assistance was almost two times higher in countries with low 
TCS treatment score in the 2017 wave (aOR=1.85; 95% CI 1.31 
to 2.61) and much higher in countries with medium and high 
TCS treatment scores. In contrast, respondents were less likely 
to report having used pharmacotherapy (aOR=0.73; 95% CI 
0.58 to 0.93) and health professional/cessation service advice 
(aOR=0.53; 95% CI 0.38 to 0.74) in 2017 when compared 
with 2012. The effect size for use of health professional/cessa-
tion services did not differ among countries with different TCS 
treatment scores.
People living in countries with more comprehensive smoking 
cessation policies (ie, with high TCS treatment scores) were more 
likely to have used any cessation assistance (aOR=1.78; 95% CI 
1.15 to 2.76), pharmacotherapy (NRT or other medication) 
Table 1 Use of smoking cessation assistance among former smokers and current smokers who have tried to quit in the European Union, 2012–
2017
Current smokers who had ever tried to quit
% (95% CI)
Former smokers
% (95% CI)
Total
% (95% CI)
2012
n=4341
2017
n=3489
2012
n=5580
2017
n=6000
2012
n=9921
2017
n=9489
Pharmacotherapy 22.5 (20.5 to 24.5) 16.6 (14.6 to 18.8) 8.5 (7.5 to 9.7) 7.5 (6.5 to 8.7) 14.6 (13.6 to 15.8) 11.1 (10.1 to 12.3)
Smoking cessation 
services
8.5 (7.3 to 9.9) 5.7 (4.5 to 7.1) 6.7 (5.8 to 7.8) 4.5 (3.7 to 5.4) 7.5 (6.7 to 8.4) 5.0 (4.3 to 5.8)
Electronic cigarettes 7.1 (5.9 to 8.4) 15.6 (13.5 to 17.8) 1.1 (0.7 to 1.5) 5.8 (4.8 to 6.9) 3.7 (3.2 to 4.3) 9.7 (8.7 to 10.8)
Oral or nasal tobacco 0.6 (0.4 to 0.9) 1.1 (0.7 to 1.9) 0.7 (0.6 to 1.1) 1.2 (0.9 to 1.6) 0.7 (0.5 to 0.9) 1.2 (0.8 to 1.5)
Without assistance 65.7 (63.4 to 67.9) 66.2 (63.4 to 68.8) 73.9 (72.1 to 75.7) 80.7 (78.9 to 82.3) 70.3 (68.9 to 71.7) 74.8 (73.3 to 76.3)
Any assistance 40.4 (38.1 to 42.7) 37.5 (34.8 to 40.3) 25.6 (23.8 to 27.4) 20.8 (19.2 to 22.6) 32.2 (30.8 to 33.7) 27.5 (26.0 to 29.1)
Table 2 Associations of self-reported smoking cessation assistance with sociodemographic factors and tobacco treatment policies in 27 EU MS 
among former smokers and current smokers who had tried to quit, 2012–2017 (n=19 410)
Any assistance* aOR 
(95% CI)
Without assistance aOR 
(95% CI)
Pharmacotherapy aOR 
(95% CI)
health services aOR 
(95% CI)
electronic cigarettes aOR 
(95% CI)
Year 
  2012 (ref) 1.00 1.00 1.00 1.00 1.00
  2017 0.61 (0.52 to 0.71) 1.72 (1.47 to 2.02) 0.73 (0.58 to 0.93) 0.53 (0.38 to 0.74) 1.85 (1.31 to 2.61)
Tobacco Control Scale treatment score 
  Low (ref) 1.00 1.00 1.00 1.00 1.00
  Medium 1.20 (0.86 to 1.68) 0.92 (0.68 to 1.26) 1.59 (0.95 to 2.65) 1.47 (0.93 to 2.31) 1.19 (0.72 to 1.97)
  High 1.78 (1.15 to 2.76) 0.57 (0.38 to 0.86) 3.44 (1.78 to 6.66) 2.27 (1.27 to 4.06) 1.58 (0.83 to 3.01)
Year*Tobacco Control Scale treatment score 
  2017*Low (ref) 1.00 1.00 1.00 1.00 1.00
  2017*Medium 1.39 (1.17 to 1.66) 0.64 (0.54 to 0.77) 1.17 (0.90 to 1.51) 1.22 (0.85 to 1.77) 1.28 (0.87 to 1.89)
  2017*High 1.43 (1.14 to 1.78) 0.64 (0.51 to 0.80) 0.69 (0.50 to 0.93) 0.81 (0.51 to 1.28) 2.42 (1.53 to 3.82)
Age (years) 
  ≥55 (ref.) 1.00 1.00 1.00 1.00 1.00
  40–54 1.45 (1.34 to 1.58) 0.73 (0.67 to 0.79) 1.69 (1.52 to 1.88) 0.91 (0.78 to 1.06) 2.32 (1.94 to 2.77)
  25–39 1.32 (1.21 to 1.45) 0.81 (0.73 to 0.88) 1.33 (1.18 to 1.50) 0.66 (0.55 to 0.79) 2.89 (2.40 to 3.47)
  15–24 1.38 (1.20 to 1.60) 0.80 (0.69 to 0.92) 0.88 (0.71 to 1.10) 0.54 (0.38 to 0.74) 4.38 (3.43 to 5.60)
Sex 
  Female (ref.) 1.00 1.00 1.00 1.00 1.00
  Male 0.98 (0.92 to 1.05) 1.03 (0.96 to 1.10) 0.89 (0.82 to 0.98) 1.00 (0.88 to 1.13) 1.06 (0.93 to 1.21)
Difficulties paying bills 
  Never/almost never (ref.) 1.00 1.00 1.00 1.00 1.00
  From time to time/most of 
the time
1.19 (1.10 to 1.28) 0.84 (0.78 to 0.91) 1.22 (1.11 to 1.35) 1.29 (1.12 to 1.49) 1.35 (1.17 to 1.57)
Age when stopped education (years) 
  Up to 15 (ref.) 1.00 1.00 1.00 1.00 1.00
  16–19 1.18 (1.06 to 1.31) 0.88 (0.79 to 0.98) 1.33 (1.15 to 1.54) 1.21 (1.00 to 1.46) 1.30 (1.03 to 1.63)
  ≥20 1.12 (1.01 to 1.25) 0.93 (0.83 to 1.04) 1.24 (1.06 to 1.44) 1.26 (1.03 to 1.55) 1.15 (0.90 to 1.46)
Area of residence 
  Rural (ref.) 1.00 1.00 1.00 1.00 1.00
  Urban 1.07 (1.00 to 1.15) 0.94 (0.88 to 1.01) 1.04 (0.95 to 1.15) 1.12 (0.98 to 1.28) 1.13 (0.97 to 1.31)
*Includes pharmacotherapy, smoking cessation services, electronic cigarettes, oral or nasal tobacco and other.
aOR, adjusted OR; EU MS, EU Member States.
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(aOR=3.44; 95% CI 1.78 to 6.66) and health professionals/
smoking cessation services (aOR=2.27; 95% CI 1.27 to 4.06) 
compared with those living in countries with low TCS treatment 
scores. There was no statistically significant difference regarding 
the use of e-cigarettes.
Younger people (15–24 years) were more likely than those 
aged ≥55 years to have used any cessation assistance including 
e-cigarettes (aOR 4.38; 95% CI 3.43 to 5.60) but less likely to 
have received advice from health professionals/smoking cessa-
tion services (aOR 0.54; 95% CI 0.38 to 0.74). People with diffi-
culties paying bills were more likely to have used any cessation 
assistance than those who never or almost never have problems 
paying their bills. Sex, with the exception of pharmacotherapy, 
and area of residence were not significantly associated with the 
use of cessation assistance.
Variations in changes between 2012 and 2017 across EU MS 
are shown in figure 1. The reported past use of pharmacotherapy 
was less likely in eight of the 27 EU MS in 2017, compared with 
2012 and more likely only in Italy, while the remaining 18 MS 
experienced non-statistically significant changes. A statistically 
significant increase in the use of electronic cigarettes to quit 
smoking was reported in 12 EU MS. In nine EU MS, support from 
health professionals/smoking cessation services was less likely to 
be reported in 2017, compared with 2012, with no statistically 
significant increase in any of the EU MS (figure 1). Changes in 
pharmacotherapy and cessation services use at the MS level were 
modestly correlated (r=0.53). On the contrary, change in e-ciga-
rette use was weakly correlated with both changes in pharmaco-
therapy (r=0.22) and in cessation services (r=0.18).
dIsCussIOn
This secondary analysis of two recent Eurobarometer waves 
found that the use of any self-reported smoking cessation assis-
tance decreased in the EU between 2012 and 2017. Self-reported 
use of e-cigarettes for smoking cessation increased, while the use 
of standard cessation assistance, such as pharmacotherapy and 
support from healthcare professionals and cessation services, 
was less likely to be reported in 2017 compared with 2012. 
There was considerable variation between EU MS, with changes 
differing depending on the level of tobacco treatment policies. 
Notably, in countries with more comprehensive smoking cessa-
tion policies, adults reported substantially higher use of phar-
macotherapy and cessation services, indicating the impact of 
national policies on cessation attempts.
The increase in the reported use of electronic cigarettes as 
cessation assistance coinciding with a decrease in the use of phar-
macotherapy or support from health professionals is consistent 
with findings from the English Smoking Toolkit study conducted 
between 2011 and late 2014.9 That study concluded that there 
was no evidence that the decline in the use of NRT could be 
attributed to the rise in the use of e-cigarettes, a finding they 
confirmed also using more recent data.10 Use of medication and 
NRT for smoking cessation can be influenced by factors such as 
the availability of new pharmaceuticals, funding and smoke-free 
legislation11–14; therefore, the explanation of these changes may 
differ between EU MS. In our study, it is not clear whether using 
e-cigarettes as a substitute for tobacco impacts use of established 
services like NRT and smoking cessation clinics or whether it 
is mostly employed by smokers who would otherwise try to 
quit without assistance, especially due to the inexistence of a 
supportive policy environment for standard cessation assistance 
(pharmacotherapy and cessation services). At the individual MS 
level, there was only weak correlation between changes in e-cig-
arette use and changes in use of standard cessation assistance, 
which might suggest coincidence rather than displacement. 
More research on whether e-cigarette use is displacing standard 
cessation assistance in Europe and how this may impact long-
term abstinence is required, especially considering the increase 
in e-cigarette use.15 16
While changes in cessation assistance and support used were 
quite similar in the majority of EU MS, we nevertheless observed 
some heterogeneity between countries. As a previous interna-
tional study of differences in cessation assistance in 15 countries 
noted, such variation may reflect a combination of differences 
in tobacco control efforts and priorities, the affordability of 
different methods and more general cultural factors.17 In our 
analyses, national policies regarding availability and cost of 
cessation services were associated with both use of the assessed 
Figure 1 Changes (aOR with 95% CI) between 2012 and 2017 in having used pharmacotherapy, cessation services and e-cigarettes, respectively, 
as cessation assistance among former smokers and current smokers who had tried to quit in 27 EU member states (n=19 410). *Cessation 
services include support from the doctor or other health professional or special smoking cessation services (clinics, specialists, quitlines and so on). 
Pharmacotherapy includes nicotine replacement medications (nicotine gum, patch, inhaler and so on) or other medications. aOR, adjusted OR; EU, 
European Union.
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cessation assistance and changes over time. Our findings are in 
line with an earlier analysis of Eurobarometer data from 2012, 
which found that living in a country that offers cost-covered 
national quitlines, medication and other cessation services was 
associated with higher likelihood of using standard cessation 
assistance with proven efficacy.4 Although there seems to be an 
overall decline in use of cessation assistance for smoking cessa-
tion across the EU, this concerning trend was attenuated in MS 
with more comprehensive cessation services, highlighting the 
importance of national policies and FCTC Article 14 imple-
mentation. It has to be noted, however, that the question used 
for the analysis refers to ‘ever use of cessation assistance’, so it 
would take a considerable amount of time to detect an effect of 
any policy change, as there is already a substantial number of 
people who had used certain cessation assistance in quit attempts 
before the current policies were put into place. This limitation 
of our analysis further highlights the increase in e-cigarette use 
for cessation, as it is a product that has become available much 
more recently compared with other types of cessation assistance, 
although respondents may have been more likely to recall assis-
tance used in more recent quit attempts.
Our results have important implications for clinical practice, 
as they highlight the fact that European healthcare professionals 
are increasingly having to deal with smokers who are using e-cig-
arettes for smoking cessation and are less likely to use well estab-
lished cessation assistance.18–21 Regardless of factors related to 
access and cost of cessation services, our findings may also reflect 
the reluctance of some smokers to engage in ‘medicalised’ cessa-
tion that involves contact with health services or use of medica-
tion. Beyond questions surrounding the efficacy of e-cigarettes 
in smoking cessation,22 for which there is limited evidence from 
randomised controlled trials,23 this trend poses a new challenge 
for health professionals, whose experience in handling smoking 
cessation among smokers who use e-cigarettes or wish to use 
e-cigarettes is still limited. This challenge also extends to regu-
lating bodies, which should closely monitor research on novel 
products that are or may be used in quit attempts and consider 
updating their guidance to clinicians accordingly.
It is also important to explore country-specific factors that 
may have influenced the use of smoking cessation assistance in 
recent years and could explain the variability in changes between 
member states. In the UK, for example, increase in e-cigarette 
use was coupled with a decline in use of pharmacotherapy and 
cessation services, although these opposing trends may not be 
associated.9 10 14 On the contrary, despite an increase in e-cig-
arette use for smoking cessation in the Netherlands, use of 
pharmacotherapy and cessation services has not changed, while 
other member states, such as Germany and Poland, experienced 
decreased use of pharmacotherapy and cessation services without 
a concurrent change in the use of e-cigarettes over the study 
period. It is also interesting to note that no statistically signifi-
cant changes were reported in Greece, despite worsening access 
to healthcare services overall during the economic crisis.24 These 
examples underscore the complexity of the smoking cessation 
landscape in the EU and the multitude of factors that may shape 
future developments in each member state.
In our analysis, we found that a number of smokers have tried 
to quit smoking using multiple methods, including a variety of 
cessation assistance and trying without assistance. This is consis-
tent with findings from the USA,25 although the difference in 
the cessation assistance assessed does not allow direct compar-
isons. Moreover, our data did not allow us to explore whether 
different types of cessation assistance were used concurrently or 
in distinct quit attempts. In addition, those who successfully quit 
reported much lower use of cessation assistance compared with 
smokers who had tried to quit without success. This is likely 
explained by the fact that smokers who find it more difficult to 
quit are also more likely to seek assistance; therefore, our study 
cannot provide insight into the relative effectiveness of smoking 
cessation methods.
strengths and limitations
We used two cross-sectional surveys with large samples repre-
sentative of the EU population and consistent sampling meth-
odology; therefore, we are confident that these conclusions are 
generalisable to the entire EU population, although the samples 
at the country level were modest, typically around 1000 indi-
viduals in each member state. The samples were independently 
selected in the two waves (no cohort was followed up), hence 
any causal interpretations of the detected associations should 
be made with caution. Further cohort study data across the EU 
is needed.26 The classification of policies regarding cessation 
services may also not provide adequate granularity to capture 
small but potentially important variations in policies between EU 
MS. Additionally, we had no data regarding the time when each 
type of cessation assistance had been used, which would have 
helped us identify changes specifically associated with recent 
use of cessation assistance, nor was any information on efficacy 
available. All data were self-reported and thus may be subject to 
bias, as people may be more likely to remember cessation assis-
tance used more recently or, in the case of former smokers, those 
that were effective in helping them to quit. Former smokers were 
defined as such based on self-reports; no minimum period of 
abstinence was reported. Finally, we combined data for ciga-
rettes, cigars and pipes; however, because regular use of cigars 
and pipes is rare in the EU,27 any effect on our results is most 
likely minimal.
COnClusIOn
The majority of attempts to quit smoking in the EU continue to 
be without any cessation assistance. The proportion of smokers 
attempting to quit using assistance has further decreased over 
the past 5 years. The use of established aids such as pharmaco-
therapy have become less popular, while e-cigarettes as a poten-
tial cessation or switching method has grown between 2012 and 
2017. This highlights the need to evaluate their efficacy and 
impact on individual abstinence as well as their population-level 
implications and to explore whether they may be displacing stan-
dard cessation assistance. Finally, it is important to emphasise the 
central role of the smoking cessation policy environment. Living 
What this paper adds
 ► Use of e-cigarettes for smoking cessation has increased, 
while use of pharmacotherapy and smoking cessation 
services has decreased across the European Union between 
2012 and 2017.
 ► Changes differed widely among member states. Individuals 
living in countries with comprehensive smoking cessation 
policies were more likely to have used any cessation 
assistance.
 ► Smoking cessation is a key strategy in the battle against 
tobacco both at a population and at the individual levels. 
Identifying trends and factors associated with the use of 
cessation assistance can inform both policy makers and 
clinicians.
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in a country that offers cost-covered national quitlines, phar-
macotherapy and other cessation services was associated with 
higher likelihood of using standard cessation assistance with 
proven efficacy, highlighting the importance of national policies 
in FCTC Article 14 implementation.
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